Loading clinical trials...

Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy

Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose Escalation, Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACU-4429 in Subjects With Dry Age-Related Macular Degeneration (Geographic Atrophy)

NCT01002950•Kubota Vision Inc.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the investigational drug ACU-4429 in subjects with geographic atrophy.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Have a clinical diagnosis of geographic atrophy, as defined in the protocol

Exclusion Criteria

•Currently receiving or has received a medication prohibited by the protocol

Locations (12)

Retinal Consultants of Arizona

Phoenix, Arizona, United States

Retina-Vitreous Associates Medical Group

Beverly Hills, California, United States

Covance Clinical Research Unit, Inc.

Daytona Beach, Florida, United States

National Ophthalmic Research Institute

Fort Meyers, Florida, United States

Covance Clinical Research Unit, Inc.

Honolulu, Hawaii, United States

Kresege Eye Institute

Detroit, Michigan, United States

Associated Retinal Consultants, P.C. / William Beaumont Hospital

Royal Oak, Michigan, United States

New York Eye and Ear Infirmary

New York, New York, United States

Cleveland Clinic

Cleveland, Ohio, United States

Black Hills Regional Eye Institute

Rapid City, South Dakota, United States

Key Dates

Start Date

October 1, 2009

Primary Completion Date

June 1, 2012

Completion Date

October 1, 2012

Last Updated

March 11, 2014

Enrollment

ACTUAL participants

Conditions

Dry Age-related Macular DegenerationGeographic Atrophy

Interventions

ACU-4429

DRUG

Matching placebo

DRUG

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

NCT06779773

Geographic AtrophyMacular Degeneration

View study

RECRUITINGPHASE2

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

NCT06990269

Geographic Atrophy Secondary to Age-related Macular Degeneration

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 11, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy

Inclusion Criteria

Exclusion Criteria

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration

Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy